Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:EMMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMMAEmmaus Life Sciences$0.01$0.01$0.01▼$0.02$723K8.6774,677 shs366 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMMAEmmaus Life Sciences0.00%+0.98%-10.56%-28.97%-39.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMMAEmmaus Life Sciences$0.01$0.01$0.01▼$0.02$723K8.6774,677 shs366 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMMAEmmaus Life Sciences0.00%+0.98%-10.56%-28.97%-39.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMMAEmmaus Life Sciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMMAEmmaus Life Sciences$12.45M0.06N/AN/A($0.91) per share-0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMMAEmmaus Life Sciences-$7.49M-$0.13N/AN/AN/A-70.64%N/A-40.35%N/ALatest EMMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026EMMAEmmaus Life SciencesN/A-$0.05N/A-$0.05N/A$1.98 million3/30/2026Q4 2025EMMAEmmaus Life SciencesN/A-$0.03N/A-$0.03N/A$3.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEMMAEmmaus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMMAEmmaus Life SciencesN/A0.080.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMMAEmmaus Life Sciences7.42%Insider OwnershipCompanyInsider OwnershipEMMAEmmaus Life Sciences35.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMMAEmmaus Life Sciences6070.19 million45.62 millionNot OptionableEMMA HeadlinesRecent News About These CompaniesEmmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2026 | businesswire.comEmmaus Life Sciences Reports Annual Financial ResultsMarch 30, 2026 | businesswire.comEmmaus Enters License and Exclusive Distribution Agreement with NeoImmuneTechJanuary 2, 2026 | contractpharma.comCEmmaus Life Sciences grants NeoImmuneTech Endari distribution rightsDecember 31, 2025 | msn.comEmmaus Life Sciences enters license, distribution agreement with NeoImmuneTechDecember 31, 2025 | msn.comEmmaus, NIT sign Endari distribution agreementDecember 31, 2025 | finance.yahoo.comEmmaus Life Sciences restructures convertible debt via exchangeDecember 22, 2025 | tipranks.comEmmaus Life Sciences Reports Quarterly Financial ResultsNovember 14, 2025 | prnewswire.comEmmaus Life Sciences Reports Quarterly Financial ResultsAugust 14, 2025 | prnewswire.comEmmaus Life Sciences Inc. Annual Income Statement - MarketWatchJuly 9, 2025 | marketwatch.comEmmaus Life Sciences, Inc.: Emmaus Life Sciences Receives FDA Approval for Endari Label Enhancements - FinanzNachrichten.deJune 28, 2025 | finanznachrichten.deEmmaus Life Sciences Receives FDA Approval for Endari® Label EnhancementsJune 26, 2025 | prnewswire.comEmmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2025 | prnewswire.comEmmaus Life Sciences IncApril 18, 2025 | uk.investing.comEmmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi ArabiaJanuary 29, 2025 | finance.yahoo.comEmmaus Life Sciences, Inc.: Emmaus Life Sciences Reports Improved Quarterly Financial ResultsNovember 23, 2024 | finanznachrichten.deEmmaus Life Sciences Reports Improved Quarterly Financial ResultsNovember 19, 2024 | prnewswire.comMike Johnson impersonates Trump: ‘Make it too big to rig’November 7, 2024 | uk.news.yahoo.comJesse Green secures another term in Senate District 24 in Boone, Greene and Guthrie countiesNovember 6, 2024 | freep.comFEmmaus, PA 10-Day Weather ForecastNovember 2, 2024 | wunderground.comWMedia Sentiment Over TimeEMMA Company DescriptionsEmmaus Life Sciences OTCMKTS:EMMA$0.01 0.00 (0.00%) As of 11:18 AM EasternEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
